Impact of socioeconomic status on survival with AIDS

American Journal of Epidemiology

Volumn 148, Issue 3, 1998, Pages 282-291

  Katz, Mitchell H ^a   Hsu, Ling ^a   Lingo, Michael ^a   Woelffer, Greg ^a   Schwarcz, Sandra K ^a  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

AIDS; HIV; Socioeconomic status; Survival

Indexed keywords

AIDS; DISEASE SURVIVAL; MEDICAL GEOGRAPHY; SOCIOECONOMIC STATUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; FEMALE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POVERTY; SOCIOECONOMICS; SURVIVAL RATE; VIRUS INFECTION;

CALIFORNIA; USA;

EID: 0032147209     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009637     Document Type: Article

References (54)

1. Fein O. The influence of social class on health status: American and British research on health inequalities. J Gen Intern Med 1995;10:577-86.
2. Pappas G, Queen S, Hadden W, et al. The increasing disparity in morality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med 1993;329:103-9.
3. Adler NE, Boyce T, Chesney MA, et al. Socioeconomic inequalities in health. No easy solution. JAMA 1993;269: 3140-5.
4. Schechter MT, Hogg RS, Aylward B, et al. Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. J Clin Epidemiol 1994:47:59-67.
5. Hogg RS, Strathdee SA, Craib KJP, et al. Lower socioeconomic status and shorter survival following HIV infection. Lancet 1994;344:1120-4.
6. Fife D, Mode C. AIDS incidence and income. J Acquir Immune Defic Syndr 1992:5:1105-10.
7. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995:333:751-6.
8. Moore RD, Hidalgo J, Sugland B, et al. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991:324:1412-16.
9. Lemp GF, Hirozawa AM, Cohen JB, et al. Survival for women and men with AIDS. J Infect Dis 1992; 166:74-9.
10. Blum S, Singh TP, Gibbons J, et al. Trends in survival among persons with acquired immunodeficiency syndrome in New York City: the experience of the first decade of the epidemic. Am J Epidemiol 1994;139:351-61.
11. Easterbrook PJ, Keruly JC, Creagh-Kirk T, et al. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. JAMA 1991:266:2713-18.
12. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. JAMA 1994;272:1915-21.
13. Curtis JR, Patrick DL. Race and survival time with AIDS: a synthesis of the literature. Am J Public Health 1993;83: 1425-8.
14. Turner BJ, Markson LE, McKee LJ, et al. Health care delivery, zidovudine use, and survival of women and men with AIDS. J Acquir Immune Defic Syndr 1994;7:1250-62.
15. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: a prospective observation study of 2,625 patients. BMJ 1997:314:409-13.
16. Vella S. Effect of sex, age, and transmission category on progression to AIDS. AIDS 1995;9:51-6.
17. d'Arminio Monforte A, Mainini F, Formenti T, et al. Survival in a cohort of 1205 AIDS patients from Milan. (Letter). AIDS 1996:10:798-9.
18. Whitmore-Overton SE, Tillett HE, Evans BG, et al. Improved survival from diagnosis of AIDS in adult cases in the United Kingdom and bias due to reporting delays. AIDS 1993;7: 415-20.
19. Rogers PA, Gore SM, Whitmore-Overton SE, et al. United Kingdom AIDS survival in adults. AIDS 1996:10:1571-8.
20. Lundgren JD, Barton SE, Katlama C, et al. Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Arch Intern Med 1995;155:822-8.
21. Ghirardini A, Puopolo M, Rossetti G, et al. Survival after AIDS among Italian haemophiliacs with HIV infection. AIDS 1995:9:1351-6.
22. Graham NMH, Zeger SL, Kuo V, et al. Zidovudine use in AIDS-free HIV-l-seropositive homosexual men in the multicenter AIDS cohort study (MACS), 1987-1989. J Acquir Immune Defic Syndr 1991:4:267-76.
23. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Serv Res 1995;30:593-614.
24. Mor V, Fleishman JA, Dresser M, et al. Variation in health service use among HIV-infected patients. Med Care 1992;30: 17-29.
25. Katz MH, Bolan GA, Douglas JM Jr, et al. Impact of insurance type on receipt of medical care by HIV-infected men. Am J Man Care 1996;2:25-35.
26. Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
27. Martin JN, Colford JM Jr, Ngo L, et al. Effect of older age on survival in human immunodeficiency virus (HIV) disease. Am J Epidemiol 1995;142:1221-30.
28. Krieger N. Women and social class: a methodological study comparing individual, household, and census measures as predictors of black/white differences in reproductive history. J Epidemiol Community Health 1991;45:35-42.
29. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;92:703-10.
30. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
31. Hessol NA, Buchbinder SP, Colbert D, et al. Impact of HIV infection on mortality and accuracy of AIDS reporting on death certificates. Am J Public Health 1992;82:561-4.
32. Ellen JM, Kohn RP, Bolan GA, et al. Socioeconomic differences in sexually transmitted disease rates among black and white adolescents, San Francisco, 1990 to 1992. Am J Public Health 1995;85:1546-8.
33. Haan M, Kaplan GA, Camacho T. Poverty and health: prospective evidence from the Alameda County Study. Am J Epidemiol 1987;125:989-98.
34. Kass NE, Faden RR, Fox R, et al. Loss of private health insurance among homosexual men with AIDS. Inquiry 1991; 28:249-54.
35. Yelin EH, Greenblatt RM, Hollander H, et al. The impact of HIV-related illness on employment. Am J Public Health 1991; 81:79-84.
36. Graham NMH, Jacobson LP, Kuo V, et al. Access to therapy in the multicenter AIDS cohort study, 1989-1992. J Clin Epidemiol 1994;47:1003-12.
37. Amo PS, Hughes RG. Local policy responses to the AIDS epidemic: New York and San Francisco. N Y State J Med 1987;87:264-72.
38. Scitovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA 1986;256:3103-6.
39. Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr 1988;l:466-85.
40. Arno PS. The nonprofit sector's response to the AIDS epidemic: community-based services in San Francisco. Am J Public Health 1986;76:1325-30.
41. Andrews RM, Keyes MA, Fanning TR, et al. Lifetime Medicaid service utilization and expenditures for AIDS in New York and California. J Acquir Immune Defic Syndr 1991;4: 1046-58.
42. Sundwall DN, Bailey D. Meeting the needs of people with AIDS: local initiatives and federal support. Public Health Rep 1988:103:293-8.
43. Gillies P, Tolley K, Wolstenholme J. Is AIDS a disease of poverty? AIDS Care 1996:8:351-63.
44. Blustein J. The reliability of racial classifications in hospital discharge abstract data. Am J Public Health 1994;84: 1018-21.
45. Anderson RN, Kochanek KD, Murphy SL. Report of final mortality statistics, 1995. Mon Vital Stat Rep 1997;45(suppl 2): 1-80.
46. Amler RW, Eddins DL. Cross-sectional analysis: precursors of premature death in the United States. In: Amler RW, Dull HB, eds. Closing the gap: the burden of unnecessary illness. New York, NY: Oxford University Press, 1997:181-7.
47. Moore RD, Chaisson RE, Hidalgo J. The efficacy of zidovudine is time limited. (Letter). JAMA 1994;272:1001-2.
48. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437-42.
49. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994;271:1088-92.
50. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
51. Decks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997:277:145-53.
52. Feder HM Jr, Milch LR. Viral load and combination therapy for human immunodeficiency virus. (Letter). N Engl J Med 1997:336:959-60.
53. Green J, Amo P. The "Medicaidization" of AIDS. JAMA 1990:264:1261-6.
54. Fife D, Mode C. AIDS prevalence by income group in Philadelphia. J Acquir Immune Defic Syndr 1992;5:1111-15.